Elicio’s pancreatic cancer vaccine misses primary endpoint
Elicio Therapeutics (ELTX) reported that its Phase 2 study of camupepimut for pancreatic cancer did not meet the primary endpoint of disease-free survival. The study had a hazard ratio of 0.85, missing the target. Subgroup analyses showed potential benefits in patients without baseline ctDNA positivity. The company plans to discuss findings with the FDA for a potential Phase 3 study.
How this was made
The 30-second read
Why it matters
The miss is likely to trigger a sell‑off in ELTX as investors reassess the drug's commercial prospects.
Market read
Primary disclosure of a pivotal trial miss; high relevance for ELTX shareholders and oncology biotech sector.
What to watch
Potential for a Phase 3 design adjustment and FDA discussion could mitigate short‑term fallout.
Background
Elicio Therapeutics announced Phase 2 AMPLIFY‑7P results, missing the primary disease‑free survival endpoint in pancreatic cancer.
Ticker impact
Phase 2 trial of camupepimut missed its primary disease‑free survival endpoint, likely pressuring ELTX stock.
downward pressure as investors price in the negative trial outcome
First disclosure of a pivotal trial miss for a biotech; market typically reacts sharply to such data.
Market effects
May weigh on other pancreatic cancer biotech peers and broader oncology sector.
Primarily U.S. biotech market; limited broader regional effect.
Limited to biotech investors; no macro impact.
Counterpoint
If the drug shows strong immune response despite miss, some investors may view it as a long‑term play.
Key entities
- companyElicio Therapeutics Inc.
Biotech firm developing camupepimut for pancreatic cancer.
